Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological, neuropsychiatric, immunological, and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 76 | Added +32% | 491,918 | $7,319,740 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -5% | 92,773 | $1,380,462 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-03-09 | CHILDS JOHN W | director | 28,400 | $864,212 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.